1.01MMarket Cap-28P/E (TTM)
0.370High0.360Low59.12KVolume0.370Open0.361Pre Close21.68KTurnover2.17%Turnover RatioLossP/E (Static)2.80MShares8.40052wk High0.07P/B985.63KFloat Cap0.35152wk Low--Dividend TTM2.73MShs Float275000.000Historical High--Div YieldTTM2.80%Amplitude0.350Historical Low0.366Avg Price1Lot Size
Catheter Precision Stock Forum
Catheter Precision Continues to Expand Clinical Data and Acceptance of VIVO
Catheter Precision (NYSE/American:VTAK) has announced updates for their VIVO non-invasive mapping system. At the European Society of Cardiology (ESC) meeting, Prof. Tarv Dhanjal presented data from a 20-patient study, showing 90% procedural success at a mean follow-up of 7.3 ± 4.7 months in patients with scar-related VT. The full study, expected to enroll 50 patients, is anticipated to ...
Benzinga· 3 mins ago
Catheter Precision, Inc. (the"Company") (NYSE:VTAK), a US based medical device pioneering electrophysiology products, announced that it has completed a distribution agreement for LockeT with Dubai based company Forum Medical.
The distribution agreement also includes partnerships with additional distributors in the Middle East, expan...
As previously announced, the company has recently expanded their US sales and clinical team in preparation for the national product launch of LockeT.
The newest purchase order comes from the MultiCa...
loading...
Presentation at European Society of Cardiology Demonstrates VIVO Accuracy in Complex VT Patients
Catheter Precision, Inc. (NYSE American:VTAK) announced interim results from a study presented at the European Society of Cardiology (ESC) Symposium. The study, led by Professor Tarv Dhanjal at Warwick Medical School, demonstrated the accuracy of VIVO in localizing ventricular tachycardia (VT) origin in patients with scar-related re-entrant VT. Key findings include:
...
No comment yet